Major Depressive Disorder (MDD) or Depression

A Clinical Overview for Major Depressive Disorder (MDD) or Depression

Overview

Major depressive disorder (MDD), commonly known as Depression, is a prevalent, disabling, and frequently recurrent psychiatric condition characterized by persistent low mood, markedly diminished interest or pleasure in activities, and a constellation of cognitive, behavioral, and somatic symptoms that significantly impair daily functioning. MDD or Depression exists on a spectrum from mild to severe, and most individuals experience multiple episodes over their lifetime. MDD is recognized as one of the leading causes of disability-adjusted life years (DALYs) globally, underscoring the urgency of early recognition, accurate diagnosis, and evidence-based intervention (National Institute for Health and Care Excellence [NICE], 2022; Zhao et al., 2025).

This clinical blog provides an integrated overview of MDD across the full care continuum—from epidemiology and etiology, through assessment and diagnosis, to pharmacological and psychosocial treatment, monitoring, and referral. The structure follows a SOAP-aligned clinical framework, with headings organized according to APA Publication Manual (7th ed.) guidelines.

Epidemiology and Burden of Major Depressive Disorder

Global Prevalence

MDD affects hundreds of millions of individuals globally. The Global Burden of Disease Study 2021 identified depressive disorders as a leading contributor to years lived with disability (YLDs), particularly among adolescents and young adults aged 15–34 years. Disability-adjusted life years (DALYs) attributable to depressive disorders have increased consistently over the past three decades, reflecting both genuine rises in incidence and improvements in detection (Zhao et al., 2025). High-income regions report higher diagnosed prevalence, most likely reflecting stronger mental health infrastructure, better surveillance systems, and reduced stigma—rather than true epidemiological differences in disease burden.

Demographic Patterns Related to MDD

Sex and Gender

MDD is approximately twice as prevalent in women as in men across most global regions, a disparity attributable to a combination of neuroendocrine factors (e.g., reproductive hormone fluctuations), differential exposure to psychosocial stressors, and potential under-diagnosis in men due to atypical symptom presentation and sociocultural barriers to help-seeking (American Psychological Association [APA], 2019; Zhao et al., 2025).

Age of Onset

Onset of MDD most commonly occurs during early adulthood, with a peak incidence in the 18–25 age range. However, MDD can manifest at any age. Children and adolescents frequently present with irritability, somatic complaints, and academic decline rather than classic depressed mood. Older adults more often report cognitive symptoms, fatigue, and physical complaints, which can complicate diagnosis and lead to under-recognition (APA, 2019).

Geographic and Socioeconomic Variation

Prevalence varies substantially across geographic regions, influenced by socioeconomic determinants, access to mental healthcare, cultural conceptualizations of distress, and the quality of national disease registries. Lower-income countries likely face significant underdiagnosis and underreporting, while the true global burden may be considerably higher than published estimates reflect (Zhao et al., 2025).

Determinants of Major Depressive Disorder

Etiology and Pathophysiology

MDD arises from a complex, multifactorial interplay of biological, psychological, and environmental determinants. No single causal pathway accounts for the disorder, and the relative contribution of each factor varies substantially across individuals and episodes.

Neurobiological Mechanisms

The monoamine hypothesis proposes dysregulation of serotonergic, noradrenergic, and dopaminergic neurotransmission, remains foundational to understanding major depressive disorder (MDD) pathophysiology and has directly informed pharmacological treatment. More recent models emphasize the role of hypothalamic-pituitary-adrenal (HPA) axis dysfunction, characterized by chronic cortisol hypersecretion in response to sustained psychosocial stress. Neuroinflammatory processes, include elevated circulating pro-inflammatory cytokines (interleukin-6 [IL-6] and tumor necrosis factor-alpha [TNF-α]), associated with the onset and maintenance of depressive episodes (De Menezes Galvão et al., 2021; Mehra et al., 2025).

Reduced brain-derived neurotrophic factor (BDNF) levels impair neuroplasticity—the brain’s capacity for synaptic remodeling, contributing to structural changes including decreased hippocampal volume and disrupted activity in prefrontal-limbic circuits governing mood regulation, reward processing, and executive function. These neuroplasticity deficits may underlie treatment resistance in a subset of patients (De Menezes Galvão et al., 2021).

Genetic and Epigenetic Contributors

The heritability of MDD is estimated at 37–40%, indicating a substantial but incomplete genetic contribution. A family history of major depressive disorder, bipolar disorder, or anxiety significantly elevates individual risk. Genome-wide association studies (GWAS) have implicated polymorphisms in serotonin transporter genes (SLC6A4), FKBP5, and BDNF, among others. Epigenetic modifications, including stress-induced DNA methylation patterns that may mediate the interaction between genetic vulnerability and adverse environmental exposures (Mehra et al., 2025).

Risk Factors for Major Depressive Disorder

Risk factors for MDD span multiple domains and frequently interact in a cumulative fashion:

Psychological Risk Factors for Major Depressive Disorder

• History of trauma or adverse childhood experiences (ACEs), including abuse, neglect, or household dysfunction
• Maladaptive cognitive schemas, including pervasive negative attributional styles and low self-worth
• Chronic stress exposure and poor emotion-regulation capacity
• Prior depressive or anxiety episodes (strongest predictor of recurrence)

Social and Environmental Risk Factors

• Social isolation, loneliness, and absence of confiding relationships
• Unemployment, financial hardship, and housing instability
• Exposure to intimate partner violence or community violence
• Systemic marginalization, discrimination, and minoritized identity stressors

Medical and Biological Risk Factors

• Chronic physical illness (cardiovascular disease, diabetes, chronic pain syndromes)
• Inflammatory and autoimmune conditions
• Thyroid dysfunction, anemia, and nutritional deficiencies (B12, folate, vitamin D)
• Certain medications (corticosteroids, beta-blockers, isotretinoin, hormonal contraceptives)
• Alcohol and substance use disorders (both risk factor and common comorbidity)

Effects of Depression on Individuals, Families, and Communities

Impact on Individuals

MDD substantially impairs occupational performance, interpersonal functioning, self-care, and overall quality of life. Major depressive disorder is associated with increased risk of cardiovascular disease, metabolic syndrome, and premature mortality. Critically, major depressive disorder confers a significantly elevated risk of suicidal ideation, attempts, and death: approximately 15% of individuals with severe, recurrent depression die by suicide (Bains & Abdijadid, 2020). Cognitive deficits in concentration, memory, and executive function frequently persist beyond the symptomatic episode, affecting vocational and educational attainment.

Impact on Families and Caregivers

Family members and informal caregivers of individuals with MDD experience substantial psychological burden, including elevated rates of anxiety, depression, and burnout. Financial strain arising from reduced productivity, increased healthcare utilization, and caregiving responsibilities is common. Children of parents with untreated MDD carry significantly elevated risk of developing depressive, anxiety, and behavioral disorders, highlighting the intergenerational consequences of the condition.

Impact on Communities and Systems

At the population level, MDD is a leading driver of lost workplace productivity, absenteeism, and presenteeism. It substantially increases healthcare utilization across primary, secondary, and emergency care settings. Economic modeling consistently identifies depression as one of the costliest disorders in terms of both direct healthcare expenditure and indirect productivity losses (Zhao et al., 2025; NICE, 2022).

Assessment

Principles of Comprehensive Assessment

Thorough assessment of MDD requires integration of standardized screening instruments, clinical interview, mental status examination (MSE), and physical evaluation. Assessment should be personalized depending on developmental stage, cultural context, and clinical complexity. Also, it should be an ongoing process and be repeated systematically throughout the care episode.

Symptom Severity Assessment Tools

Preclinical Screening and Community Settings

The Patient Health Questionnaire-9 (PHQ-9) is the most widely validated and recommended screening instrument for MDD in primary care and community settings (NICE, 2022). It is a nine-item self-report tool yielding scores from 0 to 27, with established cut-points for severity stratification:

• Minimal: 0–4
• Mild: 5–9
• Moderate: 10–14
• Moderately severe: 15–19
• Severe: ≥20

The Hospital Anxiety and Depression Scale (HADS) is frequently used in medical and oncology settings, as it minimizes the confounding effect of somatic symptoms attributable to physical illness. The Edinburgh Postnatal Depression Scale (EPDS) is the preferred tool for perinatal populations.

Clinical Assessment: Mental Status Examination

A comprehensive MSE should be conducted at initial presentation and at clinically significant phases. Key domains include:

• Appearance and behavior: psychomotor retardation or agitation, self-neglect, eye contact
• Speech: rate, tone, latency, volume
• Mood (subjective) and affect (objective): congruence, range, lability
• Thought form and content: suicidal ideation (passive or active), hopelessness, worthlessness, nihilism
• Perceptual disturbances: mood-congruent hallucinations in severe cases
• Cognition: orientation, concentration, short-term memory
• Insight and judgment: appreciation of illness and treatment rationale

A thorough psychiatric history encompasses symptom onset, duration, severity, trajectory, precipitants, prior episodes and their treatment response, family psychiatric history, psychosocial stressors, and complete medication and substance use review (NICE, 2022; APA, 2019).

Physical Examination and Laboratory Investigations

Physical examination and targeted investigations are essential to exclude treatable medical causes of depressive symptoms. Recommended baseline investigations include:

• Full blood count (FBC) and inflammatory markers (CRP, ESR)
• Thyroid function tests (TFTs): hypothyroidism is a common reversible cause of depression
• Serum B12 and folate
• Fasting glucose and HbA1c
• Liver and renal function tests (baseline prior to pharmacotherapy)
• Toxicology screen if substance use is suspected

Post-Clinical Monitoring

Systematic follow-up assessment using repeat PHQ-9 scoring is recommended at every clinical review to quantify treatment response. A reduction of ≥5 points from baseline, or achievement of a score below 10, represents clinically meaningful improvement. Achievement of a PHQ-9 score below 5 defines remission. Ongoing assessment of suicide risk, functional status, medication tolerability, and treatment adherence is essential throughout the care episode and beyond (NICE, 2022).

Diagnosis Of Major Depressive Disorder

DSM-5-TR Diagnostic Criteria for MDD

Diagnosis is established according to criteria set out in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR; APA, 2022). A diagnosis of MDD requires the presence of five or more of the following symptoms during the same two-week period, with at least one symptom being either (1) depressed mood or (2) loss of interest or pleasure (anhedonia):

Criterion A: Core Symptom Cluster

• A1. Depressed mood: Present most of the day, nearly every day, as reported subjectively or observed by others. In children and adolescents, mood may manifest as persistent irritability rather than sadness.
• A2. Anhedonia: Markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day.
• A3. Weight or appetite changes: Significant unintentional weight loss or gain (>5% body weight in a month), or persistent decrease or increase in appetite.
• A4. Sleep disturbance: Insomnia or hypersomnia nearly every day.
• A5. Psychomotor changes: Observable psychomotor agitation or retardation—not merely subjective restlessness or slowing.
• A6. Fatigue: Fatigue or loss of energy nearly every day.
• A7. Worthlessness or guilt: Feelings of worthlessness or excessive, inappropriate guilt (which may be delusional in severity) nearly every day.
• A8. Cognitive impairment: Diminished ability to think, concentrate, or make decisions, nearly every day.
• A9. Suicidality: Recurrent thoughts of death (not merely fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or specific plan for committing suicide.

Criterion B: Functional Impairment

Symptoms cause clinically significant distress or impairment in social, occupational, educational, or other important areas of functioning.

Criterion C: Exclusion of Organic Cause

Symptoms are not attributable to the direct physiological effects of a substance (e.g., drug of abuse, medication) or another medical condition.

Criterion D: Exclusion of Other Psychotic Disorders

The episode is not better explained by schizoaffective disorder, schizophrenia, schizophreniform disorder, delusional disorder, or other specified or unspecified schizophrenia spectrum or other psychotic disorders.

Criterion E: Absence of Manic or Hypomanic Episodes

There has never been a manic episode or hypomanic episode. If manic or hypomanic episodes are present, a diagnosis of bipolar disorder should be considered.

Differential Diagnosis

Accurate differential diagnosis is essential to guide appropriate treatment. Key conditions to distinguish from MDD include (APA, 2022; Bains & Abdijadid, 2020):

Bipolar Disorder

Depressive episodes in bipolar disorder are clinically indistinguishable from MDD episodes; differentiation requires eliciting a history of manic or hypomanic episodes. This distinction is clinically critical, as antidepressant monotherapy may precipitate manic switching or cycle acceleration in bipolar disorder.

Persistent Depressive Disorder (Dysthymia)

Characterized by chronically depressed mood present for two or more years (one year in children and adolescents), typically with less severe but more pervasive symptoms than MDD. Double depression—MDD superimposed on persistent depressive disorder—is common and carries a poorer prognosis.

Adjustment Disorder With Depressed Mood

Occurs in direct temporal relation to an identifiable psychosocial stressor, typically resolves within six months of stressor removal, and does not meet the full criteria for MDD in terms of symptom number, duration, or severity.

Medical Conditions Mimicking MDD

Hypothyroidism, anemia, vitamin B12 or folate deficiency, chronic infections, and neurological disorders (e.g., Parkinson’s disease, multiple sclerosis, early dementia) can produce symptoms indistinguishable from MDD. Laboratory investigation is mandatory before attributing symptoms to a primary psychiatric cause.

Substance-Induced Mood Disorder

Depression secondary to alcohol use disorder, stimulant withdrawal, opioid use, or iatrogenic medications (e.g., corticosteroids, beta-blockers, hormonal agents) must be excluded through careful history and toxicological screening.

Anxiety Disorders

Generalized anxiety disorder, panic disorder, and social anxiety disorder frequently co-occur with MDD and share overlapping symptoms including fatigue, insomnia, and concentration difficulties. Both conditions typically require concurrent treatment.

Grief and Bereavement

Normal grief following bereavement may present with depressive features but is distinguished by preserved capacity for positive affect in response to social support, absence of sustained worthlessness or self-loathing, and fluctuating rather than pervasive low mood. DSM-5-TR no longer excludes bereavement-related presentations from an MDD diagnosis if full criteria are met.

Treatment Plan for Major Depressive Disorder

Treatment Goals

Treatment goals for MDD are individualized and should be collaboratively negotiated with the patient. Core objectives include:

• Achieve full symptom remission, defined as a PHQ-9 score below 5 with restoration of baseline psychosocial functioning
• Prevent relapse during the acute phase and recurrence in the maintenance phase
• Enhance quality of life, social connectedness, and occupational reintegration
• Ensure patient safety, including ongoing assessment and mitigation of suicide risk
• Address comorbid psychiatric and medical conditions and identified psychosocial stressors

Implementation

Psychopharmacological Interventions for MDD

Pharmacotherapy is indicated for moderate-to-severe MDD and may be considered for mild MDD if symptoms have persisted beyond four weeks, if the patient has a prior history of moderate-to-severe episodes, or if psychosocial interventions are insufficient or inaccessible (NICE, 2022).

First-Line Pharmacotherapy

Selective serotonin reuptake inhibitors (SSRIs) are the recommended first-line pharmacological treatment for MDD across adult, adolescent, and older adult populations. Their recommendation reflects a favorable tolerability profile, wide therapeutic index, and relative safety in overdose compared to older antidepressant classes. Commonly prescribed SSRIs include:

• Sertraline: Preferred in older adults and those with cardiovascular comorbidity due to its favorable drug–drug interaction profile
• Escitalopram: Among the most selective SSRIs; well-tolerated with a low side-effect burden
• Fluoxetine: Long half-life makes it particularly useful in patients with adherence difficulties; preferred in adolescents

Full therapeutic response typically requires 4–6 weeks at an adequate dose. Antidepressants should not be routinely prescribed for mild depression. Treatment should continue for a minimum of six months following remission to prevent relapse (NICE, 2022; APA, 2019).

Second-Line Pharmacotherapy

If an adequate trial of a first-line SSRI (typically four to six weeks at the maximum tolerated dose) produces insufficient response, the following strategies are recommended:

• Switch to an alternative SSRI (e.g., from sertraline to escitalopram)
• Switch to a serotonin-norepinephrine reuptake inhibitor (SNRI): venlafaxine or duloxetine
• Switch to mirtazapine (particularly useful in patients with severe insomnia or weight loss)
• Switch to bupropion (useful when sexual dysfunction with SSRIs is a concern)
• Consider augmentation with a second agent (lithium, atypical antipsychotic, or buspirone)

Tricyclic antidepressants (TCAs) are effective but are reserved for cases where SSRIs and SNRIs are contraindicated or not tolerated, given their narrow therapeutic index and lethality in overdose (NICE, 2022).

Third-Line Pharmacotherapy: Treatment-Resistant Depression

Treatment-resistant depression (TRD) is operationally defined as failure to respond to two or more adequate antidepressant trials of different classes. Management options include:

• Lithium augmentation: Remains one of the most evidence-supported augmentation strategies
• Atypical antipsychotic augmentation: Quetiapine, aripiprazole, and olanzapine have regulatory approval as adjunctive treatments
• Esketamine (Spravato®) nasal spray: Approved for TRD; produces rapid antidepressant effects mediated through NMDA receptor antagonism; must be administered under clinical supervision
• Electroconvulsive therapy (ECT): Highly effective for severe, psychotic, or life-threatening TRD; also indicated for severe suicidality requiring rapid response

All antidepressant discontinuations should be undertaken gradually over at least four weeks to minimize discontinuation syndrome (NICE, 2022).

Psychotherapeutic Interventions for MDD

Individual Psychotherapy

Psychotherapy is a first-line treatment for mild-to-moderate MDD and is strongly recommended as an adjunct to pharmacotherapy for moderate-to-severe presentations. Evidence-based individual therapies include:

• Cognitive Behavioral Therapy (CBT): The most extensively researched psychological treatment for MDD, with a robust evidence base across diverse populations. Targets maladaptive automatic thoughts, cognitive distortions, and avoidance behaviors through structured, goal-directed techniques.
• Interpersonal Therapy (IPT): Focuses on resolving interpersonal disputes, role transitions, grief, and social skills deficits that contribute to and maintain depressive episodes.
• Behavioral Activation (BA): Systematically increases engagement with rewarding and values-aligned activities to counter behavioral withdrawal and anhedonia. Particularly effective in primary care settings.
• Mindfulness-Based Cognitive Therapy (MBCT): Recommended by NICE (2022) for patients with recurrent MDD (≥3 prior episodes) to reduce relapse risk; integrates mindfulness meditation with CBT techniques.

Group Psychotherapy

Group-based CBT programs are recommended for mild-to-moderate MDD as accessible, cost-effective interventions with the added benefit of normalizing experience and reducing isolation. Structured psychoeducation groups and peer support programs provide complementary benefits and facilitate community integration (NICE, 2022).

Complementary and Multidisciplinary Care

Nursing and Care Coordination for Depression

Nurses are central to the delivery of collaborative care models for MDD. Key nursing roles include psychoeducation about the nature of depression and the rationale for treatment, medication adherence counseling, systematic PHQ-9 monitoring, suicide risk screening at every contact, liaison with the broader multidisciplinary team, and coordination of community support services.

Nutritional Interventions

Accumulating evidence supports a bidirectional relationship between diet quality and depressive symptoms. A Mediterranean-style dietary pattern—rich in vegetables, legumes, whole grains, fish, and olive oil—is associated with reduced depression risk. Nutritional deficiencies in B12, folate, vitamin D, and omega-3 fatty acids should be assessed and corrected in all patients. Referral to a registered dietitian is appropriate for patients with significant weight changes, metabolic comorbidities, or disordered eating behaviors.

Physical Activity and Exercise

Structured aerobic exercise is strongly endorsed by NICE (2022) for mild-to-moderate MDD and as an adjunct to treatment in more severe presentations. Meta-analyses demonstrate that regular moderate-intensity aerobic exercise (150 minutes per week) produces significant antidepressant effects, likely mediated through increases in BDNF, normalization of HPA axis activity, and reduction in neuroinflammatory markers. Exercise prescriptions should be individually tailored to promote sustainable engagement, accounting for baseline fitness, physical health comorbidities, and personal preference.

Social Work

Social workers address the psychosocial determinants of mental health that frequently perpetuate or exacerbate depressive episodes. Areas of intervention include housing instability, financial hardship, employment barriers, domestic violence, social isolation, and child welfare concerns. Social workers facilitate access to community resources, benefits entitlements, and peer support networks, while providing advocacy within complex health and social care systems.

Occupational Therapy

Occupational therapists (OTs) focus on the functional consequences of MDD in daily life. Interventions target deficits in work performance, self-care, and leisure engagement through occupational analysis, graded activity scheduling, and environmental modification. OTs are central to facilitating graded return-to-work programs, which are associated with improved mental health outcomes when structured appropriately.

Evaluation for Major Depressive Disorder

Prognosis

With appropriate, timely, and sustained treatment, the majority of patients with MDD achieve full symptom remission within several months. However, MDD frequently follows a recurrent course: epidemiological data indicate that 50–85% of individuals who experience a first depressive episode will experience at least one recurrence. Approximately one-third develop chronic or treatment-resistant forms of the disorder. Favorable prognostic indicators include strong social support networks, absence of comorbid substance use disorders, good early treatment response, and sustained treatment adherence. Predictors of poorer outcomes include early age of onset, severe or psychotic features, multiple prior episodes, comorbid personality disorder, and significant medical comorbidity (Bains & Abdijadid, 2020).

Follow-Up Schedule

Systematic follow-up is essential to monitor treatment response, manage side effects, and promptly identify relapse or deterioration:

• Week 1–2: Initial post-treatment review to assess tolerability, early response, and suicide risk; most critical period for dropout and adverse events
• Weeks 4–8: Formal PHQ-9 reassessment; evaluate for dose optimization or treatment switch if response is inadequate
• Months 3–6: Three-monthly review once stabilized; reinforce adherence and relapse prevention strategies
• Maintenance phase: Continue pharmacotherapy for a minimum of 6 months post-remission; 2+ years for patients with three or more prior episodes or severe/chronic presentations (NICE, 2022)

Referral Criteria for MDD

Referral to specialist psychiatric services is indicated in the following circumstances:

• Diagnostic uncertainty or clinical complexity (e.g., psychotic features, suspected bipolar disorder)
• Failure to respond to two or more adequate antidepressant trials (TRD)
• Significant psychiatric comorbidity (e.g., substance use disorder, eating disorder, personality disorder)
• Active suicidal ideation with plan or intent, or recent suicide attempt
• Consideration of specialized interventions: ECT, esketamine, or inpatient admission (APA, 2019; NICE, 2022)

Red Flags: Immediate Action Required

Clinical Presentations Requiring Urgent or Emergency Response

The following presentations require immediate clinical action and should not be deferred to routine review:

Active Suicidal or Homicidal Ideation

Any patient presenting with active suicidal ideation accompanied by a specific plan, means, or stated intent requires same-day urgent psychiatric assessment. Inpatient hospitalization should be considered when the patient cannot be safely managed in the community. A comprehensive safety plan should be developed collaboratively with all patients who express any degree of suicidal ideation.

Psychotic Features

Depressive episodes with psychotic features (mood-congruent or mood-incongruent delusions or hallucinations) cannot be adequately managed with antidepressant monotherapy. An antipsychotic agent must be added, and specialist psychiatric review is required. ECT may be first-line in severe psychotic depression.

Manic or Hypomanic Switching

The emergence of elevated mood, pressured speech, decreased sleep without fatigue, impulsivity, or grandiosity in a patient being treated with antidepressants should prompt immediate reassessment for bipolar disorder. Antidepressant monotherapy should be discontinued, and a mood-stabilizing agent initiated with specialist guidance.

Severe Self-Neglect

Inability to maintain adequate nutrition, hydration, personal hygiene, or medication adherence indicates that outpatient management is no longer appropriate. An urgent care review, home assessment, or inpatient admission should be arranged.

Rapid Clinical Deterioration

Any acute worsening of depressive symptoms, functional status, or risk profile despite ostensibly adequate treatment warrants urgent reassessment to identify contributing factors, including treatment non-adherence, emerging comorbidity, or inadequate diagnosis.

Resources and Support

Crisis Support Services

The following resources are available for individuals in crisis:

• National Suicide Prevention Lifeline (USA): Call or text 988 (available 24/7, free, confidential)
• Crisis Text Line (USA): Text “HELLO” to 741741
• International Association for Suicide Prevention Crisis Centres
• Mental health emergency: Call 988 (USA), attend the nearest emergency department, or contact local emergency services

Professional and Clinical Resources

• NICE (2022) Depression in Adults: Treatment and Management Guideline
• APA (2019) Clinical Practice Guideline for the Treatment of Depression
• DSM-5-TR (APA, 2022): The authoritative diagnostic reference for MDD and related conditions:

References

American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). https://doi.org/10.1176/appi.books.9780890425787

American Psychological Association. (2019). Clinical practice guideline for the treatment of depression across three age cohorts. https://www.apa.org/depression-guideline/guideline.pdf

Bains, N., & Abdijadid, S. (2020). Major depressive disorder. StatPearls [Internet]. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK559078

De Menezes Galvão, A. C., et al. (2021). Pathophysiology of major depression by clinical stages. Frontiers in Psychology, 12, 641779. https://doi.org/10.3389/fpsyg.2021.641779

Mehra, A., Khanna, J., Singh, G., Sachdeva, V., & Bedi, N. (2025). A comprehensive review on major depressive disorder: Exploring etiology, pathogenesis and clinical approaches. Current Behavioral Neuroscience Reports, 12(1), 18. https://doi.org/10.1007/s40473-025-00308-y

National Institute for Health and Care Excellence (NICE). (2022). Depression in adults: Treatment and management. https://www.ncbi.nlm.nih.gov/books/NBK583074/

Zhao, L., Lou, Y., Tao, Y., Wang, H., & Xu, N. (2025). Global, regional and national burden of depressive disorders in adolescents and young adults, 1990–2021. Frontiers in Public Health, 13, 1599602. https://doi.org/10.3389/fpubh.2025.1599602